Shots:
- Curatis & Neupharma have entered into an exclusive license & development agreement for Corticorelin (C‑PTBE‑01) in Japan to treat Peritumoral Brain Edema
- As per the deal, Neupharma will develop & commercialize corticorelin in Japan & fund a pivotal trial to support PMDA approval, in exchange of upfront & regulatory & commercial milestones totaling up to CHF 83.5M (~$107.445M), plus royalties of up to 20% on Japanese sales
- The therapy is initially planned for children and adolescents, with a PMDA meeting planned for summer 2026 to discuss the registration-enabling study, initiation expected in 2027 & a parallel P-III preparation for the US & EU underway
Ref: Businesswire | Image: Curatis & Neupharma | Press Release
Related News: Rapport Therapeutics Partners with Tenacia Biotechnology to Advance RAP-219 in Greater China
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
